ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results

ResMed has reported fresh quarterly figures and updated investors on demand trends for its sleep apnea devices and masks. The stock remains closely watched as the company navigates obesity drug headwinds and supply-chain issues in the US market.

ResMed, a leading provider of devices and software for sleep apnea and respiratory care, recently reported its latest quarterly results and gave an updated view on demand trends for masks, ventilators and digital solutions. The numbers and management comments highlighted resilient underlying demand despite ongoing concerns about the impact of weight-loss drugs on the sleep apnea market, according to ResMed investor update as of 04/25/2025 and coverage by Reuters as of 04/26/2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Medical technology, respiratory care
• Headquarters/country: San Diego, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Sleep apnea devices, CPAP masks, cloud-based software
• Home exchange/listing venue: New York Stock Exchange (ticker: RMD)
• Trading currency: US dollar (USD)

ResMed: core business model

ResMed focuses on solutions for people suffering from sleep apnea and other chronic respiratory diseases. The company develops and sells positive airway pressure devices, masks and accessories that help patients maintain open airways during sleep. These products are typically prescribed by physicians and reimbursed by payers in major healthcare systems, including Medicare and private insurers in the United States, as reported in the company’s annual filing for the fiscal year ended June 30, 2024, published on 08/22/2024, according to ResMed annual report as of 08/22/2024.

In addition to hardware, ResMed operates a growing digital health platform. The company offers cloud-connected devices and software that allow healthcare providers and home medical equipment companies to monitor patient adherence and adjust therapy remotely. This digital ecosystem includes patient engagement tools and analytics that aim to improve treatment outcomes and reduce hospitalizations by enabling more proactive care management, as described in the company’s digital health overview released on 03/14/2024, according to ResMed product overview as of 03/14/2024.

The business model is therefore a combination of device sales, recurring revenue from masks and accessories, and subscription-like income from software solutions. Many patients with diagnosed sleep apnea use devices and replacement masks for years, creating a recurring revenue stream. This setup helps smooth out some of the volatility that can come from economic cycles or changes in one-off equipment purchases, a point the company underlined in its investor presentation dated 02/06/2025, according to ResMed investor presentation as of 02/06/2025.

Main revenue and product drivers for ResMed

Revenue at ResMed is driven primarily by the volume of sleep apnea diagnoses and therapy initiation, the installed base of devices in use and the ongoing replacement of masks and accessories. For the quarter ended March 31, 2025, ResMed reported revenue of approximately 1.3 billion USD, an increase versus the same period a year earlier, with growth supported by both devices and masks, according to ResMed earnings release as of 04/25/2025. The company cited strong demand in the United States and Europe as supply constraints eased.

Masks and accessories are a key recurring driver. Patients typically replace masks and cushions at regular intervals for comfort and efficacy, and reimbursement guidelines in the US support this replacement cycle. As the installed base of therapy devices grows, this recurring stream becomes more important to the overall mix. ResMed also generates revenue from ventilators and life support systems used in chronic respiratory disease, though this segment can be more sensitive to hospital capital spending patterns than the core sleep therapy business, as indicated in segment disclosures for the fiscal year ended June 30, 2024, published on 08/22/2024, according to ResMed Form 10-K as of 08/22/2024.

Software-as-a-service offerings in out-of-hospital care also contribute to revenue and margin. ResMed owns platforms for home health and hospice agencies that help manage patient information, scheduling and billing. These software solutions generally operate on subscription models, which can support more stable revenue and attractive margins. In the quarter ended March 31, 2025, management pointed to ongoing growth in software revenue as part of its diversified model, according to ResMed management commentary as of 04/25/2025.

Conclusion

ResMed remains a central player in the global sleep apnea and respiratory care market, with a model that combines device sales, recurring mask revenue and digital health software. Recent quarterly figures showed ongoing growth and highlighted the importance of the US market for both hardware and software. At the same time, the company faces questions about how widespread adoption of weight-loss drugs could affect long-term demand for sleep apnea treatment, as well as general healthcare reimbursement and competitive dynamics. For US-focused investors, ResMed offers exposure to a specialized area of medical technology with structural demand drivers, but also sector-specific uncertainties that warrant careful monitoring of future earnings releases and regulatory developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.